CorMatrix Cardiovascular said today that it launched a trial of its Cor Tricuspid ECM cardiac valve intended for treating adults with endocarditis and pediatric patients with congenital heart valve disease, adding that the first patient in the trial has already been treated. The first procedure in the trial took place at the Francicscan Health Heart Center […]
CorMatrix Cardiovascular Inc.
CorMatrix wins FDA IDE approval for Cor Tricuspid ECM cardiac valve trial
CorMatrix Cardiovascular said today that it won FDA investigational device exemption approval to launch an early feasibility study of its Cor Tricuspid ECM cardiac valve intended for treating adults with endocarditis and pediatric patients with congenital heart valve disease. The Atlanta-based company touts its Cor Tricuspid valve as the first cardiac valve of its kind […]
CorMatrix lands CE Mark for CanGaroo surgical envelope
CorMatrix Cardiovascular said today that it won CE Mark approval in the European Union for its CanGaroo ECM surgical envelope for implanted cardiac devices. Roswell, Ga.-based CorMatrix won 510(k) clearance from the FDA in August 2014 for the CanGaroo device, which is designed to act as a scaffold to stimulate natural wound healing using CorMatrix’s extra-cellular matrix. […]
CorMatrix launches Tyke cardiac tissue repair device for neonates
CorMatrix Cardiovascular said today it launched its CorMatrix Tyke cardiac tissue repair patch designed for correcting congenital heart defects in neonates and infants, touting the 1st successful procedures utilizing the patch. The CorMatrix Tyke is a patch designed to repair pericardial structures and as an epicardial covering or for intracardiac defects, septal defects, annulus repair, suture-line […]
Ligand Pharmaceuticals pays $18m for CorMatrix assets
Ligand Pharmaceuticals (NSDQ:LGND) said this week that it’s getting into the medical device arena with the nearly $18 million acquisition of multiple tissue repair assets from CorMatrix. San Diego-based Ligand said it paid $17.5 million for synthetic royalties on existing extracellular matrix products, including the CanGaroo ECM envelope for implantable electronic devices, and the right […]
CorMatrix launches U.S. tricuspid valve device trial
CorMatrix Cardiovascular said today it enrolled the 1st patient in a trial of its CorMatrix ECM tricuspid valve designed from regenerative tissue. The early feasibility trial aims to demonstrate proof of principle and initial clinical safety at 8 U.S. centers, the Roswell, Ga.-based company said. CorMatrix is performing the trial under an investigative device exemption […]
Asahi Kasei shuffles the deck at Zoll Medical | Personnel Moves
Japan’s Asahi Kasei Corp. (TYO:3407), which in 2012 paid $2.3 billion to acquire Zoll Medical, is shuffling the deck at the resuscitation device maker. Former CEO Rick Packer, who led Zoll for 13 years before overseeing the merger with Asahi Kasei, was promoted to primary executive officer and charged with building the healthcare business into “a 3rd […]
CorMatrix wins FDA nod for Tyke neonate cardiac tissue
CorMatrix Cardiovascular said today it won FDA 510(k) clearance for its Tyke biomaterial for use in neonates and infants. The patch is designed to repair pericardial structures and as an epicardial covering or for intracardiac defects, septal defects, annulus repair, suture-line buttressing. The Tyke is derived from the company’s ECM technology platform and is composed […]
CorMatrix lands FDA win, touts 1st human implant of CanGaroo surgical pouch
Georgia medical device maker CorMatrix touted an FDA win this month, landing regulatory clearance for its CanGaroo surgical envelope for securing implantable cardiac devices.
Press Release: CorMatrix reports FDA clearance of CorMatrix CanGaroo ECM Envelope
Roswell, Georgia – CorMatrix Cardiovascular announced today that it has received U.S. Food and Drug Administration (FDA) clearance to market the CorMatrix CanGaroo ECM Envelope for use with cardiac implantable electronic devices (CIED’s) including pacemakers and implantable cardioverter defibrillators (ICD’s).
CorMatrix seeks $25M in equity round
CorMatrix Cardiovascular is seeking $25 million in an equity offering.
The Roswell, Ga.-based medical device company makes cardiovascular devices designed to treat damaged heart tissue. The CorMatrix flagship product is a biomaterial implant designed to help the heart heal itself.
